EU To Test Merging & Splitting Of Licences Under Mutual Recognition/Decentralized Procedures
This article was originally published in SRA
Executive Summary
The CMDh - the EU group that co-ordinates the approval of human medicines evaluated through the mutual recognition and decentralized procedures - has launched a pilot project that will allow drug companies to merge or split MRP/DCP lines to suit their business strategies1.